B7-H abnormalities in melanoma and clinical relevance

Methods in Molecular Biology

Volumn 1102, Issue , 2014, Pages 367-380

  Seliger, Barbara ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Coinhibitory molecules; Immune escape; Melanoma; MHC antigens

Indexed keywords

FAS ANTIGEN; HLA ANTIGEN CLASS 1; HLA G ANTIGEN; INDUCIBLE T CELL COSTIMULATOR LIGAND; MESSENGER RNA; PROGRAMMED DEATH 1 LIGAND 1; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1;

ANTIGEN FUNCTION; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOSURVEILLANCE; MELANOCYTE; MELANOMA; MELANOMA CELL; METABOLITE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; UPREGULATION;

ANTIBODIES, NEOPLASM; B7 ANTIGENS; FLOW CYTOMETRY; HUMANS; IMMUNITY; IMMUNOHISTOCHEMISTRY; MELANOMA; SKIN NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT;

EID: 84891779838     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-727-3_19     Document Type: Article

References (45)

1. Harding FA et al (1992) CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356(6370):607-609
2. Sharpe AH, Freeman GJ (2002) The B7-CD28 superfamily. Nat Rev Immunol 2(2):116-126
3. Driessens G, Kline J, Gajewski TF (2009) Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev 229(1): 126-144
4. Seliger B, Quandt D (2012) The expression, function, and clinical relevance of B7 family members in cancer. Cancer Immunol Immunother 61(8):1327-1341
5. Zou W, Chen L (2008) Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 8(6):467-477
6. Flies DB, Chen L (2007) The new B7s: Playing a pivotal role in tumor immunity. J Immunother 30(3):251-260
7. Keir ME et al (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677-704
8. Postow MA, Harding J, Wolchok JD (2012) Targeting immune checkpoints: Releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer J 18(2): 153-159
9. Greenwald RJ, Freeman GJ, Sharpe AH (2005) The B7 family revisited. Annu Rev Immunol 23:515-548
10. Seliger B et al (2008) The complex role of B7 molecules in tumor immunology. Trends Mol Med 14(12):550-559
11. Dong H et al (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 8(8): 793-800
12. Yi KH, Chen L (2009) Fine tuning the immune response through B7-H3 and B7-H4. Immunol Rev 229(1):145-151
13. Chapoval AI et al (2001) B7-H3: A costimulatory molecule for T cell activation and IFNgamma production. Nat Immunol 2(3): 269-274
14. Leitner J et al (2009) B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction. Eur J Immunol 39(7):1754-1764
15. Prasad DV et al (2003) B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 18(6):863-873
16. Sica GL et al (2003) B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18(6):849-861
17. Zang X et al (2003) B7×: A widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A 100(18): 10388-10392
18. Wilcox RA et al (2012) The B7 homologues and their receptors in hematologic malignancies. Eur J Haematol 88(6):465-475
19. Nishimura H, Honjo T (2001) PD-1: An inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 22(5):265-268
20. Arigami T et al (2011) Clinical significance of the B7-H4 coregulatory molecule as a novel prognostic marker in gastric cancer. World J Surg 35(9):2051-2057
21. Iwai Y et al (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 99(19): 12293-12297
22. Blank C et al (2006) Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 119(2): 317-327
23. Gadiot J et al (2011) Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 117(10):2192-2201
24. Kronig H et al (2012) PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic disease. Int J Cancer 130(10):2327-2336
25. Quandt D et al (2011) B7-h4 expression in human melanoma: Its association with patients' survival and antitumor immune response. Clin Cancer Res 17(10):3100-3111
26. Hino R et al (2010) Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 116(7):1757-1766
27. Martin-Orozco N et al (2010) Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells. Cancer Res 70(23):9581-9590
28. He C et al (2011) The inhibitory role of b7-h4 in antitumor immunity: Association with cancer progression and survival. Clin Dev Immunol 2011:695834
29. Zheng X et al (2012) Expression of costimulatory molecule B7-H4 in human malignant tumors. Onkologie 35(11):700-705
30. Mumprecht S et al (2009) Programmed death 1 signaling on chronic myeloid leukemiaspecific T cells results in T-cell exhaustion and disease progression. Blood 114(8):1528-1536
31. Thompson RH et al (2005) Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer 104(10): 2084-2091
32. Thompson RH et al (2004) Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 101(49):17174-17179
33. Curtin JA et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353(20):2135-2147
34. Tjin EP et al (2011) T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: Implications for immunotherapy. Clin Cancer Res 17(17): 5736-5747
35. Fourcade J et al (2010) Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 207(10): 2175-2178
36. Taube JM et al (2012) Colocalization of infl ammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4(127):127-137
37. Strauss L et al (2008) Expression of ICOS on human melanoma-infiltrating CD4+CD25high Foxp3+ T regulatory cells: Implications and impact on tumor-mediated immune suppression. J Immunol 180(5):2967-2980
38. Viguier M et al (2004) Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173(2): 1444-1453
39. Fu T, HE Q, Sharma P (2011) The ICOS/ ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res 71(16):5445-5454
40. Zang X et al (2010) Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol 23(8): 1104-1112
41. Fujimura T et al (2012) Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas. J Invest Dermatol 132(4):1239-1246
42. Blank C, Gajewski TF, Mackensen A (2005) Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: Implications for tumor immunotherapy. Cancer Immunol Immunother 54(4):307-314
43. Fourcade J et al (2009) PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol 182(9): 5240-5249
44. Brandt CS et al (2009) The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 206(7):1495-1503
45. Li Y, Wang Q, Mariuzza RA (2011) Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6. J Exp Med 208(4):703-714